Get started
DBV Technologies SA Sponsored ADRDBV Technologies SA Sponsored ADRDBV Technologies SA Sponsored ADR

DBV Technologies SA Sponsored ADR

No trades
OverviewFinancialsNewsIdeasMindsTechnicalsForecastsSeasonals

Market insights

DBV Technologies | Chart & Forecast SummaryKey Indicators On Trade Set Up In General 1. Push Set Up 2. Range Set up 3. Break & Retest Set Up Notes On Session # DBV Technologies - Double Formation * A+ Set Up | Wedge Structure Template | Subdivision 1 * (3) Wave Short End - Triple Formation * Neckline | Left & right At 0.90 |Subdivision 2 * Retracement 1 | 50% At 1.15 * Retracement 2 | Short Set Up Alignment | Subdivision 3 Active Sessions On Relevant Range & Elemented Probabilities; London(Upwards) - NYC(Downwards) Conclusion | Trade Plan Execution & Risk Management On Demand; Overall Consensus | Sell
CAPITALCOM:DBVShort
by UnknownUnicorn87383881
DBV Technologies rally on Positive FDA CommunicationDBV Technologies Spikes on Positive FDA Communication DBV Technologies received positive responses from the U.S. Food and Drug Administration regarding its application for a peanut allergy treatment. The U.S. FDA provided type A meeting requests to the questions the French company submitted in October following its receipt of a complete response letter in connection with its biologics license application (BLA) for Viaskin Peanut DBV712, its once-daily epicutaneous patch to treat peanut allergy in children ages four to 11. "We are very encouraged by the positive feedback received from the FDA, and we appreciate the clarity provided," said Daniel Tassé, CEO of DBV Technologies. “We look forward to working with our investigators, clinical trial sites, and key stakeholders as we continue in our development of investigational Viaskin Peanut." DBV says it will address details about a new human factor validation study and additional chemistry, manufacturing and controls data in subsequent communication with the FDA. "We intend to advance a remediation plan for Viaskin Peanut and work closely with FDA to review protocols and re-file our BLA as soon as possible, so that we can bring Viaskin Peanut, if approved, to patients suffering from peanut allergies," Tassé said. www.thestreet.com finance.yahoo.com
NASDAQ:DBVT
by AlenCiken
DBV Technologies Reports H1-20DBV Technologies Reports H1-20 themarketsignal.com DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20. This compares with €172.0 million in the previous half year ending December 31, 2019, reflecting €53.8 million increase. The company used €79.4 million cash in operating activities, while €1.3 million was generated from investment activities. DBVT reported €7.6 million operating income in H1-20 as against €7.1 million in H1-19. This income generation is attributed to income recognized from Research Tax Credit of the Company. During the first half of this year, the company reported €86.5 million net loss, as against €79.8 million in H1-19.
NASDAQ:DBVT
by Sector_Reports
DBV Technologies Reports H1-20DBV Technologies Reports H1-20 themarketsignal.com DBV TECHNOLOGIES ADR (NASDAQ:DBVT) is reflecting bullish signals with a RSI of 19.89. The clinical-stage biopharmaceutical company reported financial figures for the H1-20. DBVT reported €225.9 million cash and cash equivalents at the end of H1-20. This compares with €172.0 million in the previous half year ending December 31, 2019, reflecting €53.8 million increase. The company used €79.4 million cash in operating activities, while €1.3 million was generated from investment activities. DBVT reported €7.6 million operating income in H1-20 as against €7.1 million in H1-19. This income generation is attributed to income recognized from Research Tax Credit of the Company. During the first half of this year, the company reported €86.5 million net loss, as against €79.8 million in H1-19.
NASDAQ:DBVT
by Sector_Reports
DBVT - Fallen angle pattern long from current price up to $31.62DBVT is forming a nice fallen angel formation. It had a nice rally & now pulled back to moving average. We think it will continue upward from here. * Trade Criteria * Date First Found- November 21, 2017 Pattern/Why- Fallen angel Entry Target Criteria- Present price ($24.43) Exit Target Criteria- 1st Target $27.83, 2nd Target $31.62 Stop Loss Criteria- $22.58 Please check back for Trade updates. (Note: Trade update is little delayed here.)
NASDAQ:DBVTLong
by AcornWealthCorp